Month: September 2026

GREENWICH, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) — Stardust Power Inc. (NASDAQ: SDST) (“Stardust Power” or the “Company”), an American developer of battery-grade lithium carbonate, today provided an update under its previously announced agreement with Oklahoma Gas and Electric Company (“OG&E”) relating to electrical infrastructure development for Stardust Power’s proposed lithium refinery in Muskogee, Oklahoma.

The agreement advances the development of critical electrical infrastructure. OG&E is securing long-lead electrical infrastructure required to support large-scale industrial power delivery to the refinery. As electrical infrastructure is typically one of the longest-lead and most critical components of large industrial developments, securing these items represents an important milestone.

“As we continue preparing the Muskogee site for future EPC activities, securing critical electrical infrastructure remains an important component of our overall strategy,” said Chris Celano, Chief Operating Officer of Stardust Power.

Stardust Power’s refinery site spans approximately 66 acres within the Southside Industrial Park in Muskogee, Oklahoma and, once at nameplate capacity, is expected to produce up to 50,000 metric tons per annum of battery-grade lithium carbonate. The refinery is being developed in two phases of approximately 25,000 metric tons per annum for each train.

About Stardust Power Inc.  

Stardust Power (NASDAQ: SDST) is building one of America’s largest battery-grade lithium carbonate refineries in Muskogee, Oklahoma, strategically located in the center of the United States’ growing energy and manufacturing corridor. The refinery is expected to have production capacity of up to 50,000 metric tons per annum and addresses the critical shortage of U.S. lithium refining capacity. Stardust Power is focused on building a resilient American battery supply chain.

For more information, visit www.stardust-power.com 

Stardust Power Contacts

For Investors:
Johanna Gonzalez
investor.relations@stardust-power.com

For Media:
Michael Thompson
media@stardust-power.com

Cautionary Note Regarding Forward-Looking Statements 

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects. These statements may include, without limitation, statements regarding management’s expectations about future business strategies, financial performance, operating results, growth opportunities, market developments, competitive position, regulatory outlook, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by the use of forward-looking words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “may,” “model,” “outlook,” “plan,” “predict,” “project,” “seek,” “target,” “will,” “could,” “should,” or similar expressions.

Forward-looking statements are not guarantees of future performance. They are based on current expectations, estimates, forecasts, and assumptions that involve significant risks and uncertainties, many of which are beyond the Company’s control and are difficult to predict. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including but not limited to: macroeconomic conditions; inflationary pressures; changes in interest rates; supply chain disruptions; evolving consumer demand; competitive and technological developments; regulatory or legal changes; litigation exposure; cybersecurity threats; and fluctuations in foreign exchange rates. In addition, other risks and uncertainties not presently known to us or that we currently believe to be immaterial could affect the accuracy of any such forward-looking statements. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. Except as required by law, the Company assumes no obligation and expressly disclaims any duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, even if subsequent events cause expectations to change.

You should consult our filings with the U.S. Securities and Exchange Commission (SEC), including the “Risk Factors” section of its most recent Annual Report on Form 10-K and subsequent filings on Form 10-Q, for additional detail about the factors that could affect our financial and other results.

Recognition Underscores FTI Consulting and Compass Lexecon’s Global Expertise in Construction Advisory, Disputes, Digital Forensics, E-discovery, Forensic Accounting and Investigations

WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that the firm and its Compass Lexecon subsidiary led the Lexology Index Consulting Experts list for the eleventh consecutive year, with 127 professionals recognized globally.

The list identifies leading consulting experts through an independent research process that combines qualitative market feedback with quantitative analysis of relevant data points, including recommendations from corporate counsel, clients, law firms and other market participants. Professionals from FTI Consulting and Compass Lexecon were selected based on the breadth of expertise across construction advisory, E-discovery, digital forensics, financial advisory and valuation and forensic accounting.

Several FTI Consulting and Compass Lexecon professionals were also named Global Elite Thought Leaders, a distinction for experts considered in the top 5% of practitioners worldwide. Experts include: Mark Bezant, Carla Chavich, Craig Earnshaw, Renato Fazzone, Veeral Gosalia, Brett Harrison, Stefan Heissner, Basil Imburgia, Thierry Linares, Patrick McGeehin, Boaz Moselle, James Nicholson, Karl Payeur, Andrew Rhodes, Ian Smith and Dawna Wright.

FTI Consulting and Compass Lexecon professionals named to the 2026 list include the following:

Construction – Quantum, Delay & Technical – Experts

• Ali Al-Ahmad, Senior Managing Director – Toronto
• Gabriel Armanet, Senior Director – Paris
• Manoj Bahl, Senior Managing Director – London
• Lee Baker, Senior Managing Director – Singapore
• William Berkowitz, Senior Managing Director – Great Neck
• Michael Birmingham, Senior Managing Director – Pittsburgh
• Brandon Chaney, Senior Managing Director – Madrid
• Stuart Downes, Managing Director – Perth
• Burak Evrenosoglu, Managing Director – Lake Oswego
• Donia Fahmi, Senior Director – Dubai
• Alastair Farr, Senior Managing Director – London
• Juliette Fortin, Senior Managing Director – Paris
• Chris Hewkin, Managing Director – Dubai
• Thomas Hofbauer, Senior Managing Director – Munich
• Michael Jaspers, Senior Managing Director – Atlanta
• Chris Johnston, Managing Director – London
• Michael Knoll, Senior Managing Director – Seattle
• Matthew Krafft, Senior Managing Director – Bethesda
• Thierry Linares, Senior Managing Director – Paris
• Patrick McGeehin, Senior Managing Director – Bethesda
• Adrian McNulty, Managing Director – Perth
• John McSorley, Managing Director – Dublin
• Andrew Mellor, Managing Director – Dubai
• Laura Miller, Senior Managing Director – Pittsburgh
• Andrew Oddie, Managing Director – Singapore
• Stephen Podesta, Senior Director – London
• Andrew Rhodes, Senior Managing Director – Pittsburgh
• Joe Slavis, Senior Managing Director – Atlanta
• Louie Wu, Senior Advisor – Seattle

Construction – Quantum, Delay & Technical – Future Leaders

• Michael Arch, Senior Managing Director – London
• Diego Costa, Managing Director – Madrid
• Steve Harris, Senior Managing Director – London
• Michael Hennigan, Senior Managing Director – London
• Xavier Rayo, Senior Director – Paris
• Ross Towler, Managing Director – London

Digital & Data – Data and E-Discovery Experts

• Sophie Ross, Global Chief Executive Officer, Technology Segment – San Francisco
• Tom Barce, Managing Director – Chicago
• Craig Earnshaw, Senior Managing Director – London
• Renato Fazzone, Senior Managing Director – Düsseldorf
• Antonio Gesteira, Senior Managing Director – São Paulo
• Scott Gillard, Managing Director – Brisbane
• Veeral Gosalia, Senior Managing Director – Singapore
• Brett Harrison, Senior Managing Director – Washington, D.C.
• Harald Hertel, Managing Director – Frankfurt
• Nick Hourigan, Senior Managing Director – Boston
• Kathryn McCarthy, Senior Managing Director – Washington, D.C.
• Ian Smith, Senior Managing Director – London
• David Turner, Senior Managing Director – Washington, D.C.
• Colleen Casey Voshell, Senior Managing Director – Wayne

Digital & Data – Digital Forensic Experts

• Sophie Ross, Global Chief Executive Officer, Technology Segment – San Francisco
• Gokce Akkahve, Managing Director – Düsseldorf
• Tom Barce, Managing Director – Chicago
• Brian Carl, Senior Managing Director – Chicago
• Warren Dunn, Senior Managing Director – Sydney
• Craig Earnshaw, Senior Managing Director – London
• Renato Fazzone, Senior Managing Director – Düsseldorf
• Anthony J. Ferrante, Senior Managing Director – Washington, D.C.
• Javier Garcia-Chappell, Managing Director – Madrid
• Antonio Gesteira, Senior Managing Director – São Paulo
• Veeral Gosalia, Senior Managing Director – Singapore
• Erik Hammerquist, Senior Director – Los Angeles
• Brett Harrison, Senior Managing Director – Washington, D.C.
• Nick Hourigan, Senior Managing Director – Boston
• Kevin Hughes, Senior Director – London
• Sandeep Jadav, Senior Managing Director – Hong Kong
• Shelly Mady, Senior Managing Director – Dallas
• Collin Miller, Managing Director – Dallas
• Ian Smith, Senior Managing Director – London

Financial Advisory and Valuation – Quantum of Damages – Experts

• Daniel Fischel, Compass Lexecon President and Chairman – Chicago
• José Alberro, Senior Managing Director – Washington, D.C.
• David Aliaga, Senior Managing Director – Madrid
• Wayne Anthony, Managing Director – London
• Yvette Austin, Senior Managing Director and Chair of Global Finance Practice – New York
• Tsvetan Beloreshki, Senior Managing Director – New York
• Mark Bezant, Senior Managing Director – London
• Carla Chavich, Executive Vice President and Head of International Arbitration Americas Practice – New York
• James Church-Morley, Senior Managing Director – Dubai
• Neil Dryden, Senior Managing Director and Member of International Board – London and Brussels
• Andrew Durant, Senior Advisor – London
• Richard Edwards, Senior Managing Director – London
• John Ellison, Senior Advisor – London
• Juliette Fortin, Senior Managing Director – Paris
• Steve Harris, Senior Managing Director – London
• Eric Henson, Executive Vice President – Boston
• Basil Imburgia, Senior Managing Director – New York
• Ben Johnson, Senior Managing Director – Hong Kong
• Joseph P. Kalt, Senior Managing Director – Boston
• Ekaterina Lohwasser, Senior Managing Director – Munich
• Pablo D. Lopez Zadicoff, Executive Vice President – Washington, D.C.
• Noel Matthews, Senior Managing Director – London
• Meloria Meschi, Senior Managing Director – London
• Charles Mikulka, Senior Managing Director, New York
• Boaz Moselle, Executive Vice President and Member of International Board – London
• Miguel A. Nakhle, Executive Vice President – Houston
• Anke Nestler, Senior Managing Director – Frankfurt
• James Nicholson, Senior Managing Director – Singapore
• Jorge Padilla, Chair of International Board – Madrid, London and Brussels
• Mike Pilgrem, Senior Managing Director – London
• Jose Piñeiro, Senior Managing Director – Madrid
• Marcelo Schoeters, Executive Vice President – Buenos Aires and Miami
• David Sevy, Executive Vice President and Vice Chair of International Board – Paris and Brussels
• Kenneth M. Stern, Senior Managing Director – New York
• Navin Waghe, Senior Managing Director – London
• David Weiskopf, Executive Vice President – Washington, D.C.
• Dawna Wright, Senior Managing Director – Melbourne
• Andrew Wynn, Senior Managing Director – London
• Elena Zoido, Executive Vice President and Member of International Board – Madrid and Brussels
• Sebastian Zuccon, Executive Vice President – Buenos Aires and Miami

Financial Advisory and Valuation – Quantum of Damages – Future Leaders

• Joel Franks, Managing Director – London
• Nicolas Mocq, Senior Director – Paris
• Andrew Preston, Senior Managing Director – Washington, D.C.
• Tara Singh, Senior Managing Director – Toronto

Forensic Accountants – Experts

• David R. Alfaro, Senior Managing Director – San Francisco
• David Aliaga, Senior Managing Director – Madrid
• Wayne Anthony, Managing Director – London
• Michael Archibald, Senior Managing Director – New York
• John Batchelor, Senior Managing Director – Melbourne
• Mark Bezant, Senior Managing Director – London
• Steve Burlone, Senior Advisor – Boston
• Edward Case, Senior Director – London
• Kevin Dages, Executive Vice President – Chicago
• Andrew Durant, Senior Advisor – London
• John Ellison, Senior Advisor – London
• Julian Glass, Senior Managing Director – London
• David Griffin, Senior Managing Director – Cayman Islands
• Steve Harris, Senior Managing Director – London
• Stefan Heissner, Senior Managing Director – Düsseldorf
• John Hudson, Senior Managing Director – London
• Basil Imburgia, Senior Managing Director – New York
• Lindi Jarvis, Senior Managing Director – Seattle
• Michael Maloney, Senior Advisor – Washington, D.C.
• Fernando Mirgone, Managing Director – Madrid
• Andrew Morrison, Senior Managing Director – Cayman Islands
• Tara Mulkeen, Senior Managing Director – New York
• Wynand Mullins, Senior Managing Director – Sydney
• Brian Ong, Senior Managing Director – New York
• Karl Payeur, Senior Managing Director – Paris
• Patrick Pericak, Senior Managing Director – Washington, D.C.
• Jose Piñeiro, Senior Managing Director – Madrid
• Alejandro Requejo, Executive Vice President – Madrid
• Wendy Shapss, Senior Managing Director – New York
• Prasad Shetty, Senior Managing Director – Mumbai
• Jay Spinella, Senior Managing Director – Washington, D.C.
• Ian Thompson, Senior Managing Director – London
• Nicole Wells, Senior Managing Director – Chicago
• Martin Wilczynski, Senior Advisor – Washington, D.C.
• Dawna Wright, Senior Managing Director – Melbourne

In addition to this recognition, Compass Lexecon recently topped the Lexology Index Competition 2026 list with the largest roster of featured consulting experts: 65 competition economists and future leaders were recognized globally. Nine FTI Consulting professionals were also recognized as competition economists on the list.

About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of June 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.8 billion in revenues during fiscal year 2025. More information can be found at https://www.fticonsulting.com.

About Compass Lexecon
Compass Lexecon is internationally recognized as a leading economic consulting firm with preeminent competition, finance, intellectual property, international arbitration, and energy practices. With more than 600 professionals in 23 offices around the world, Compass Lexecon offers a global perspective on economic matters. For the past two decades, Compass Lexecon has been ranked as one of the leading antitrust economics firms in the world by the Global Competition Review. To learn more about Compass Lexecon or to find one of our professionals, please visit www.compasslexecon.com.

FTI Consulting, Inc.  
555 12^th Street NW  
Washington, DC 20004  
+1.202.312.9100 

Investor Contact:  
Mollie Hawkes 
+1.617.747.1791 
mollie.hawkes@fticonsulting.com 

Media Contact:  
Sam Ford 
+1.617.480.7402
samantha.ford@fticonsulting.com

Statistically significant benefits observed in bezisterim-treated Long COVID patients 
in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise

Bezisterim showed a consistent advantage over placebo on 21 out of 22 individual endpoints in the overall study population

An estimated 17–20 million U.S. adults live with Long COVID and currently have no FDA‑approved treatment options

Conference call scheduled for 8:30 a.m. today, September 15, 2026, to discuss results.

CARSON CITY, Nev., Sept. 15, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced topline results from the Company’s Phase 2 ADDRESS-LC trial (NCT06847191) evaluating its investigational drug candidate bezisterim, an oral drug that crosses the blood-brain barrier and is believed to reduce inflammation and improve insulin sensitivity, in Long COVID. In pre-specified subgroup analyses submitted to the FDA prior to data unblinding, patients with greater baseline burden on one or more symptoms (approximately 78% of trial participants) demonstrated statistically significant improvements on multiple clinically coherent endpoints. Bezisterim’s safety and tolerability profile was similar to placebo.

“I am excited by the findings in the ADDRESS-LC study. These results are among the most promising we have seen in this field so far and clearly warrant progressing to a confirmatory Phase III trial,” said Michael Peluso, MD, MHS, Associate Professor of Medicine, University of California, San Francisco.   “If bezisterim can truly help the patients with high symptomatic burden, that would be a significant benefit for the patient community”

“We have not seen anything like this from any other trial,” commented Ezra Spier, Long COVID patient advocate and ADDRESS-LC Patient Advisor. “We have not seen results that are this clear or compelling before, and this could have a significant impact for Long COVID patients.”

The ADDRESS-LC trial was a Phase 2, multicenter, randomized, double-blinded, placebo-controlled exploratory study that enrolled 203 patients to evaluate whether bezisterim could improve key neurological symptoms of Long COVID, including fatigue, brain fog, cognitive impairment and post-exertional malaise (PEM). The purpose of the Phase 2 trial was to identify the clinical endpoints where bezisterim may have the greatest effect and within which patient subpopulations. The ADDRESS-LC trial explored 22 different measures to assess clinical outcomes and a series of different biomarkers.

“The results suggest that bezisterim may help improve symptoms of fatigue, post‑exertional malaise, and cognitive impairments in patients with high symptom burden, which represents approximately 80% of patients who entered the trial. Patients who were not experiencing a meaningful symptom at the outset have little room to show improvement on that measure,” said Cuong Do, BioVie’s President and CEO. “Because fatigue, post‑exertional malaise, and cognitive dysfunction are defining features of the more severe and persistent Long COVID phenotypes¹ described in RECOVER and other large cohort studies, we find it particularly encouraging that bezisterim demonstrated its strongest effects in patients experiencing these symptoms. To our knowledge, this is the first time a drug candidate has shown the ability to help patients improve across these persistent Long COVID symptoms.² Thus, bezisterim may have the potential to become the first therapy for the neurological symptoms of Long COVID, if confirmed in our future Phase 3 trial.”

The enrolled patients were grouped into distinct symptom-severity segments based on baseline characteristics that were pre-specified in the Statistical Analysis Plan submitted to the FDA prior to unblinding; including patients with high severity of individual symptoms of fatigue, PEM and objective cognitive impairment, as well as those with two or more in combination. This wide spectrum of disease burden highlights the evolving understanding of the heterogeneity of the disease and the precision medicine approach needed to evaluate each patient segment with the most appropriate clinical endpoint.

When the full Intent‑to‑Treat (ITT) population of 203 patients is evaluated without segmentation, bezisterim shows numerical trends favoring treatment over placebo across nearly all individual endpoints, as reflected in the Cohen’s d effect sizes. Cohen’s d quantifies the magnitude of difference between treatment and control groups, and a positive value indicates that the treatment effect was greater in the bezisterim arm than in the placebo arm. In this heterogenous ITT population, no individual endpoint reached statistical significance (p<0.05), likely because patients with low baseline symptom burden had little room to improve, which may have diluted the overall signal. Twenty-one of the 22 endpoints showed numerical trends favoring bezisterim.

In pre-specified subgroup analyses, differential treatment effects emerged when focusing on patients with high baseline symptom burden. Despite reducing sample size (N), the treatment effect sizes more than doubled compared to the ITT population, as seen with higher Cohen’s d values, and the endpoints that reached statistical significance increased suggesting a coherent explanation for the clinical improvements. The most severe half of patients with fatigue symptoms showed statistically significant improvements on five endpoints (3 out of 5 of which are fatigue-specific), along with trends in post-exertional malaise and sleep. Patients with high post-exertional malaise experienced statistically significant improvements across malaise, fatigue, and objective cognitive measures. And patients who entered the trial with substantial objective cognitive impairment demonstrated statistically significant improvements on four clinically coherent objective cognitive endpoints. These subgroup findings are exploratory and require confirmation in an adequately powered prospective study. The summary “forest chart” chart below shows only those endpoints that reach statistically significant or are trending, and the charts for all endpoints can be found in the full data announcement presentation that will be discussed during today’s conference call.

“I am super excited for the Long COVID community because of this data,” stated Grace McComsey, Professor of Medicine and infectious diseases researcher. “At Case Western Reserve University, we have been a part of almost every negative study so far. It’s great to see a trial showing such potential effectiveness while using a well-tolerated oral drug.”

“Research has demonstrated that Long COVID is not a single disease, but a complex and heterogeneous syndrome with multiple clinical and biological subtypes,” said Joseph Palumbo, MD, BioVie’s EVP of Research & Development and Chief Medical Officer. “A key challenge in clinical development is not only establishing efficacy but also identifying the patients most likely to benefit and understanding the drivers of that response. Consistent with observations from our other clinical programs, the ADDRESS-LC trial showed that patients with higher disease burden at baseline experienced the greatest and most rapid improvements with bezisterim treatment. These findings support an intuitive strategy for identifying the patients most likely to benefit from treatment, grounded in both clinical presentation and underlying biology. This approach has the potential to enhance clinical outcomes and guide the design of future registrational studies.”

Bezisterim’s safety and tolerability were similar to placebo. Overall, 41.6% of bezisterim patients experienced at least one treatment-emergent adverse event compared to 55.9% for placebo. The most frequently reported drug-related adverse event was headache, experienced by 4% of bezisterim-treated patients vs. 4.9% for placebo. No serious adverse events were reported in the bezisterim arm (vs. one in placebo). The safety findings are particularly important given the extensive concomitant medication use observed in the trial population.

Conference call to discuss results

BioVie management will host a conference call at 8:30 a.m. EDT today, September 15, 2026, to discuss the findings and results. A live Q&A session with management will follow the presentation.

To register for the conference call, please visit: https://lifescievents.com/event/bkvp81/

About Long COVID

An estimated 17-20 million U.S. adults reported to be living with Long COVID,⁴ with 3.8 million experiencing significant limitation to their daily lives.⁵ Almost 50 percent of those with Long COVID develop persistent or intermittent symptoms.⁶ The neurological and neuropsychiatric symptoms are among the most common and disabling manifestations of the condition and include fatigue, PEM, sleep disturbance, and persistent sense of difficulty with thinking and memory.⁷ Chronic innate inflammation accompanied by ongoing immune dysregulation is among the leading hypotheses proposed to explain the symptoms in Long COVID, with numerous investigators describing findings in Long COVID that appear to be supportive of the intended biological targets of bezisterim. Currently, there are no FDA-approved treatment options for Long-COVID.

About the ADDRESS-LC trial

The Phase 2 ADDRESS-LC study (NCT06847191), which is fully funded by a grant from the U.S. Department of War (DoW), is a randomized (1:1), placebo-controlled, signal-finding proof-of-concept, multicenter trial evaluating the efficacy, safety and tolerability of bezisterim in adult participants with Long COVID who have cognitive impairment sequelae and fatigue. The study compared bezisterim, administered as a 20 mg oral capsule twice daily, with a matching placebo to assess its effects on neurocognitive and fatigue-related symptoms. The trial evaluated 22 clinical outcome measures, with no single endpoint pre-specified as the primary determinant of study success. Endpoints include assessing changes in overall clinical benefit, subjective and objective cognitive function, fatigue, sleep disturbance, Quality of Life and PEM. As a signal-finding study, the trial was designed to identify efficacy signals, measure treatment effect magnitude, and identify patient subgroups most likely to benefit, to inform the design of future Phase 3 trials

About Bezisterim

Bezisterim (NE3107) is an investigational oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNFα), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease (PD), Long COVID (LC), and Alzheimer’s disease (AD).

In PD, BioVie completed the SUNRISE-PD trial, which enrolled 57 patients to establish proof of mechanism and proof of concept in individuals with early-stage disease who had not previously been treated with carbidopa/levodopa. Topline results showed that patients treated with bezisterim experienced improvements with blood-based markers of inflammation, as well as a broad range of biomarkers associated with cellular health and neuronal integrity. Clinically, patients treated with bezisterim demonstrated greater improvements than those receiving placebo across multiple measures of daily functioning, motor symptoms, and non-motor symptoms.

For LC, the ADDRESS-LC trial enrolled approximately 200 patients to evaluate whether bezisterim may help reduce brain fog, fatigue, and other lingering neurological symptoms associated with LC. The hypothesis being studied is that these symptoms may be triggered by persistent circulation of spike protein fragments that trigger inflammation via NFκB activation (which bezisterim has been shown to modulate).

In AD, BioVie has conducted Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with AD.

Terms of the U.S. Department of War (DoW) Award

The work is supported by the Assistant Secretary of War for Health Affairs and endorsed by the DoW by a fully funded award in the amount of $13.13 million through the Peer-Reviewed Medical Research Program (PRMRP) under Award No. HT9425-24-1-0113. Opinions, interpretations, conclusions and recommendations in this press release are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the DoW.

About BioVie Inc.

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead investigational drug candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for Long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.

In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project,” “potential,” “may,” or words of similar meaning. Forward-looking statements in this release include, but are not limited to, statements regarding: the potential for bezisterim to address unmet clinical needs in Long COVID and Parkinson’s disease; the design and conduct of future clinical trials, including a potentially pivotal Phase 3 trial; the potential clinical significance of subgroup analyses and biomarker observations; and the Company’s ability to advance bezisterim through clinical development. The clinical endpoints reported in this release are exploratory in nature. The Phase 2 ADDRESS-LC trial did not achieve statistical significance on any endpoint in the overall intent-to-treat population; statistically significant results were observed only in pre-specified subgroup analyses. Subgroup analyses are hypothesis-generating and may not be replicated in future trials. Changes in biomarkers may not correlate with clinical benefit or support regulatory approval. The FDA has not validated these endpoints as surrogate endpoints for Long COVID. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to risks related to the early stage of development of bezisterim and other product candidates, the possibility that results observed in this Phase 2 study of 203 patients may not be replicated in larger or longer-duration trials, the exploratory nature of subgroup analyses, the Company’s ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, the possibility that clinical trial results may not be indicative of results in subsequent or larger trials, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

For Investor Relations Inquiries:
        
Contact:
Chuck Padala
Managing Director, LifeSci Advisors, LLC
chuck@lifesciadvisors.com

For Media Inquiries:
        
Contact:
Melyssa Weible
Managing Partner, Elixir Health Public Relations
mweible@elixirhealthpr.com

1	Geng L, et al. JAMA. 2025;333(8):694–700. doi:10.1001/jama.2024.24184
2	Eight Phase 2 clinical trials have been conducted by various organizations to assess 13 interventions in Long COVID. None of the interventions have demonstrated benefit thus far. Source: https://recovercovid.org/funding
3	Objective cognitive assessments are conducted using an iPad that gives patients tasks to complete and measure the person’s actual cognitive performance.
4	U.S. Department of Health and Human Services (https://www.hhs.gov/longcovid/index.html)
5	Bonuck et al. Commun Med. 2026;6:177. doi:10.1038/s43856-026-01516-7.
6	Thaweethai et al. Nat Commun. 2025;16(1):9557. doi:10.1038/s41467-025-65239-4.
7	Geng et al. JAMA. 2025 Feb 25;333(8):694-700. doi: 10.1001/jama.2024.24184.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/a305c2ae-97bb-466a-b843-541cb0eb7598
https://www.globenewswire.com/NewsRoom/AttachmentNg/f3710d26-092a-4d5f-8170-4265c9cfb673
https://www.globenewswire.com/NewsRoom/AttachmentNg/b8325cd1-e936-4e15-a18e-271e929be6b2 

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that Aras Azadian, CEO of Avicanna Inc. and Avicanna Inc. will be presenting live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on September 17^th, 2026.

The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. Avicanna’s CEO Aras Azadian will be presenting on Sep 17^th at 10:30 am Eastern Time.

A re-play of the webcast will be available following the conclusion of the conference.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

To learn more about the event, please click the link at www.virtualinvestorconferences.com.

To register for the event, please click the registration link at REGISTER HERE

About Avicanna Inc 
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars. 

• Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. 
• Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. 
• Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. 
• Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit our website or contact Ivana Maric by email at ir@avicanna.com.

Cautionary Note Regarding Forward-Looking Information and Statements 

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements with respect to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2026, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d6d26ce5-ef7f-4efd-b5c1-f032a8d43399

ST. CLOUD, Minn., Sept. 15, 2026 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI), a leading manufacturer of buses and motorcoaches and a provider of comprehensive aftermarket parts and service solutions, subsidiary New Flyer of America Inc. (New Flyer), today announced it has been awarded a contract from the Central Ohio Transit Authority (COTA) for up to 45 sixty-foot Xcelsior^® compressed natural gas (CNG) heavy-duty transit buses (90 equivalent units, or EUs).

The contract includes a firm order of 12 buses, with options for COTA to purchase up to 33 additional buses. The firm order will be added to New Flyer’s third quarter 2026 backlog, while the option buses will be added to the company’s option backlog.

The articulated Xcelsior CNG buses will replace end-of-life vehicles while supporting the launch of a new bus rapid transit (BRT) service in Columbus and surrounding communities. The purchase is supported by funding awarded through the Low or No Emission (Low-No) Grant Program, following New Flyer and COTA’s successful 2025 collaboration to secure funding for articulated CNG buses.

New Flyer has partnered with COTA since 2000, delivering more than 230 buses, including 102 CNG-powered buses. This latest award represents a new milestone in that relationship, marking COTA’s first purchase of 60-foot New Flyer articulated buses as the agency expands high-capacity transit service across Central Ohio.

“Bus rapid transit is transforming the way communities move, providing greater capacity and an enhanced passenger experience while supporting regional growth,” said Chris Stoddart, President, North American Bus and Coach, NFI. “Delivering COTA’s first 60-foot New Flyer articulated buses is an exciting milestone that reflects the agency’s vision for high-capacity transit and our shared commitment to supporting the future of mobility in central Ohio.”

“The addition of articulated buses to our fleet is another important step toward building the rapid transit system Central Ohio needs and deserves,” said Monica Tellez-Fowler, COTA President/CEO. “As our region continues to grow, we must invest in the capacity, infrastructure, and service needed to move more people efficiently and reliably. These vehicles will help us deliver on the promise of LinkUS and bring high-capacity rapid transit closer to reality for our customers and communities.”

Launched in 1974, COTA is the regional public transit authority serving the greater Columbus metropolitan area. Today, the agency provides fixed-route bus, bus rapid transit, paratransit, and microtransit services across the greater Columbus and Central Ohio area, serving approximately 1.3 million residents. COTA’s network carries more than 12 million passenger trips annually and continues to expand service to meet the transportation needs of one of the fastest-growing regions in the United States.

With the addition of New Flyer’s 60-foot Xcelsior CNG buses, COTA will further strengthen its investment in high-capacity transit designed to improve mobility, support regional growth, and enhance the customer experience along its BRT corridors.

About NFI

NFI is a leading global bus and motorcoach manufacturer and a provider of aftermarket parts and service solutions. With more than 9,000 team members across ten countries and operations spanning over 40 facilities, NFI delivers a comprehensive portfolio of bus and coach platforms.

Through its brands New Flyer^® (heavy-duty transit buses), MCI^® (motorcoaches), Alexander Dennis Limited (single- and double-deck buses), ARBOC^® (low-floor cutaway and medium-duty buses), and NFI Parts™, NFI supports a diverse and extensive portfolio, serving public transit, commuter, and coach markets. In total, NFI supports an installed base of more than 100,000 buses and coaches worldwide. NFI offers a broad range of propulsion systems, including zero-emission electric (referring to propulsion systems that do not utilize internal combustion engines, such as trolley, battery, and fuel cell), natural gas, electric hybrid, and advanced diesel technologies, providing agencies with multiple fleet technology options. NFI’s common shares trade on the Toronto Stock Exchange (TSX: NFI) and its convertible unsecured debentures trade under the symbol NFI.DB. News and information is available at www.nfigroup.com, www.newflyer.com, www.mcicoach.com, nfi.parts, www.alexander-dennis.com, arbocsv.com, and carfaircomposites.com.

About New Flyer

New Flyer is North America’s heavy-duty transit bus leader and offers the most advanced product line under the Xcelsior^® and Xcelsior CHARGE^® brands. It also offers infrastructure development through NFI Infrastructure Solutions™, a service dedicated to providing safe, sustainable, and reliable charging and mobility solutions. New Flyer actively supports over 35,000 heavy-duty transit buses (New Flyer, NABI, and Orion) currently in service, of which 8,600 are powered by electric motors and battery propulsion, and 1,900 are zero-emission. Further information is available at www.newflyer.com.

Forward-Looking Statements

This press release may contain forward-looking statements relating to expected future events and financial and operating results of NFI that involve risks and uncertainties. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, investors cannot be assured that actual results will be consistent with these forward-looking statements, and the differences may be material. Actual results may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including market and general economic conditions (including as a result of tariffs and other trade measures) and economic conditions of and funding availability for customers to purchase buses and to purchase parts or services (including as a result of recent U.S. policy developments); customers may not exercise options to purchase additional buses; the ability of customers to suspend or terminate contracts for convenience; production may be delayed or production rates may be decreased as a result of ongoing and future supply chain disruptions and shortages of parts and components, shipping and freight delays, and disruption to and shortage of labor supply; and the other risks and uncertainties discussed in the materials filed with the Canadian securities regulatory authorities and available on SEDAR at www.sedarplus.ca.  

Due to the potential impact of these factors, NFI disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. 

For media inquiries, please contact: 
Melissa Schnee 
P: 385.910.6861 
Melissa_Schnee@newflyer.com 

For investor inquiries, please contact: 
Stephen King 
P: 204.792.1300 
Stephen.King@nfigroup.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/28f23adb-4e73-4d90-86a5-64ba54d842d4

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — STORAGEVAULT CANADA INC. (“StorageVault” or the “Corporation”) (SVI-TSX) announced today that a quarterly dividend of $0.003036 per common share (“Common Share”) ‎will be payable on ‎October 15, 2026 to shareholders of record on September 29, 2026, with an ex-dividend ‎date of September 29, 2026. This dividend has been designated as an “eligible dividend” for Canadian ‎income tax ‎purposes.‎ ‎

About StorageVault Canada Inc.
StorageVault currently owns and operates 275 storage locations across Canada. StorageVault owns 243 of these locations plus over 5,000 portable storage units representing over 13.8 million rentable square feet on 802 acres of land. StorageVault also provides last mile storage and logistics’ solutions and professional records management services, such as document and media storage, imaging and shredding services.‎‎‎

For further information, contact Mr. Steven Scott or Mr. Iqbal Khan:

Tel: 1-877-622-0205
ir@storagevaultcanada.com

Follow us:
Instagram: @accessstorageca @depotiumminientrepot @sentinelstorageca @cubeitportablestorage
Facebook: /AccessStorageCA /Depotium /SentinelStorageCanada /Cubeit /FlexSpaceLogistics

VANCOUVER, British Columbia, Sept. 15, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that it has completed the acquisition of Merritt Paul Land Surveying, LLC (Merritt Paul), a land surveying firm based in Franklin, Georgia. Founded in 2015, Merritt Paul has built a track record providing surveying services to the solar, transportation and construction industries, including work for a major national transportation company, and specializes in utility-scale solar surveys across the U.S. The company is licensed to preform land surveys in 17 states. The acquisition marks ZenaTech’s 29th Drone as a Service acquisition to date.

“This acquisition deepens our Drone as a Service platform in two of the fastest-growing verticals for aerial data collection: utility-scale solar and transportation infrastructure,” said Shaun Passley, Ph.D., ZenaTech CEO. “The drone solar inspection market alone is growing at 25% annually according to market analysts, and we see similar growth trajectory opportunities across railroad and airport infrastructure as operators move away from manual survey methods towards AI automation. Merritt Paul’s founders, Tyler Bius and Levi George, each bring more than a decade of specialized survey experience with major rail and airport clients, and their team’s deep sector expertise provides a strong platform to scale drone-based solar, rail and airport surveying.”

Merritt Paul provides topographic, ALTA, boundary, as-built and construction layout surveys, with a specialized focus on utility-scale solar and battery storage projects across the U.S. Their longstanding client base spans solar developers, transportation, construction, and municipal, county and state infrastructure customers in the Atlanta and Southwest Georgia areas.

Drone-based inspection is becoming the norm across utility-scale solar farms to identify underperforming panels, wiring faults and hot spots using thermal imaging, cutting inspection time and labor costs compared to manual walk-downs. The drone solar inspection market is projected to grow from $1.2 billion in 2024 to $6.8 billion by 2032, a CAGR of approximately 25%, according to Verified Market Research. Management believes this growth, paired with continued expansion of utility-scale solar capacity across the U.S., will drive increasing demand for drone-based inspection and survey services across solar assets.

Drone-based surveying is increasingly used to map rail corridors, inspect track beds, culverts and overhead infrastructure, and support construction staking and grading work at airports without disrupting active operations. High-resolution imagery, LiDAR and photogrammetry allow survey teams to capture rail corridor and runway-adjacent data faster and more safely than traditional ground crews. The broader inspection drone market, which covers infrastructure sectors including rail and aviation, is projected to grow from roughly $4 billion in 2025 to more than $12 billion by 2032, according to Fortune Business Insights. Management believes this growth, combined with tightening safety and compliance requirements, will continue to expand demand for drone-based survey and inspection services across rail networks and airport facilities.

ZenaTech’s Drone as a Service platform provides business and government customers with subscription-based drone services using its vertically integrated ZenaDrone drones, for a host of surveying, inspections, maintenance, power washing, and precision agriculture solutions—eliminating the need for customers to own, operate and maintain commercial-grade drone fleets. Through the acquisition of established, profitable but under digitized service businesses, ZenaTech is building a scalable global DaaS network and AI autonomy platform, with recurring revenue and an existing customer base, while integrating advanced drone technologies to deliver greater speed, precision, safety, and data-driven insights. The Company continues to expand its geographic footprint, service offerings, and drone capabilities to drive long-term growth.

About ZenaTech

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries including land surveys and inspections, driving drone-based scalable and recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for agriculture and logistics, as well as ISR, cargo, and counter-UAS applications for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives.

About ZenaDrone

ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, and the IQ Aqua for underwater applications. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.

Contacts for more information:

Company, Investors, and Media:
Linda Montgomery
ZenaTech
312-241-1415

Investors:
Michael Mason
CORE IR
investors@zenatech.com

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Square, IQ Nano, IQ Quad, ZenaTech 2000, IQ Glider, IQ Sphere, IQ Aqua and Interceptor P-1; ZenaTech’s ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and its needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks and uncertainties disclosed under the heading “Risk Factors” in the Company’s Form F-1, Form 20-F and other filings filed with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at www.sec.gov. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

MONTREAL, Sept. 15, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that Knight’s New Drug Submission (NDS) for GEMTESA^® (vibegron), proposed for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults, and OAB with symptoms of urge urinary incontinence, urgency, urinary frequency, and nocturia in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH), has been accepted for review by Health Canada.

“For patients living with overactive bladder, and for adult males managing OAB alongside BPH, having access to an effective treatment option can make a real difference in daily life,” said Samira Sakhia, President and Chief Executive Officer, Knight Therapeutics Inc. “The acceptance of our submission for GEMTESA^® in Canada is an important step toward bringing this therapy to the patients who need it. At Knight, our commitment goes beyond building our portfolio. We are dedicated to improving access to innovative therapies that improve patient outcomes. We are also pleased to advance this milestone together with our partner, Sumitomo Pharma America Inc.”

In June 2025, Knight entered into exclusive supply and distribution agreements with Sumitomo’s Pharma America (SMPA) to commercialize GEMTESA^®, as well as ORGOVYX^® (relugolix) and MYFEMBREE^® (relugolix/estradiol/norethindrone acetate) in Canada.

About GEMTESA^®

GEMTESA^® (vibegron) is marketed in the US for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults and in adult males taking medication for benign prostatic hyperplasia (BPH). GEMTESA^® works by selectively targeting β₃ adrenergic receptors to reduce OAB symptoms through the relaxation of the bladder detrusor muscle to increase capacity.¹

GEMTESA^® is a registered trademark of Sumitomo Pharma Co., Ltd. All other trademarks are the property of their respective owners.

About Overactive Bladder

Overactive Bladder (OAB) is a symptom syndrome characterized by urinary urgency, usually accompanied by increased urinary frequency and nocturia, with or without urgency incontinence, in the absence of urinary tract infection (UTI) or other obvious pathology.^2,3 These symptoms are commonly associated with involuntary contractions of the detrusor muscle, although they can also result from other forms of lower urinary tract dysfunction.² The pooled global prevalence of OAB was estimated at approximately 20%, with prevalence higher in women (nearly 22%) than in men (roughly 16%).⁴ Canadian population based estimates reported in the Canadian Urological Association (CUA) guideline from May 2017 indicate an overall prevalence of approximately 14 to 18%, with prevalence increasing with age.⁵

About Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia (BPH) is a histologic diagnosis describing the proliferation of smooth muscle and epithelial cells within the prostatic transition zone, which commonly leads to enlargement of the prostate gland.⁶ In men presenting with lower urinary tract symptoms (LUTS), the symptoms are frequently presumed to arise from bladder outlet obstruction caused by the enlarged prostate.⁶ Even when the bladder outflow obstruction is relieved surgically, storage symptoms consistent with overactive bladder (OAB) may persist; detrusor overactivity has been reported in approximately 20% to 40% of men.⁷ LUTS are conventionally divided into storage, voiding, and postmicturition symptoms.² In the population-based EPIC study, storage symptoms were the most prevalent category among men (51.3%), exceeding both voiding (25.7%) and postmicturition (16.9%) symptoms.⁸

BPH becomes increasingly prevalent with age, and symptoms of OAB, which are often associated with BPH, are frequently misattributed to normal aging. In the United States, approximately 14 million men are living with BPH, and up to 75% of these individuals experience OAB symptoms.^9,10 Despite this high prevalence, OAB symptoms in men often remain unrecognized, particularly in those with underlying BPH. It is estimated that up to 80% of OAB cases in men may go undiagnosed.^11,12

About The COURAGE Trial

The COURAGE trial (NCT03902080; URO-901-3005) was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating GEMTESA^® 75 mg once daily versus placebo over 24 weeks in men ≥45 years of age with symptoms of overactive bladder (OAB) who were receiving pharmacological therapy with α-blockers, with or without 5α-reductase inhibitors, for BPH. Of 1,105 participants randomized 1:1 to vibegron or placebo, 965 (87.3%) completed the trial. The study met both co-primary endpoints at Week 12, demonstrating statistically significant reductions from baseline versus placebo in mean daily micturitions (least squares mean difference −0.74; 95% CI −1.02, −0.46; P < .0001) and urgency episodes (−0.95; 95% CI −1.37, −0.54; P < .0001). GEMTESA^® also met all prespecified secondary endpoints, with significant reductions versus placebo in nocturia episodes and urge urinary incontinence (UUI) episodes. Adverse events occurring in ≥ 2% of participants were hypertension, COVID-19, UTI, and hematuria.¹³

About The EMPOWUR Trial

EMPOWUR was a 12-week, double-blind, placebo-controlled Phase 3 study evaluating vibegron 75 mg versus placebo in adults with OAB, as part of an extensive development program involving more than 4,000 OAB patients. The study demonstrated that treatment with GEMTESA^® resulted in statistically significant reductions in daily urge urinary incontinence episodes, micturition episodes, and urgency episodes, as well as an increase in volume voided, compared to placebo. A long-term extension of the EMPOWUR study was also conducted under double-blind conditions. The most common adverse reactions reported in 2% or more of patients treated with GEMTESA^® were headache, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection.^1,14

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s website at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. Sumitomo Pharma America, Inc. GEMTESA (vibegron) tablets, for oral use [prescribing information]. Revised February 2025. Accessed June 26, 2026. https://www.gemtesa.com/files/gemtesa-prescribing-information.pdf
2. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49. doi:10.1016/s0090-4295(02)02243-4
3. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455-2463. doi:10.1016/j.juro.2012.09.079
4. Zhang L, Cai N, Mo L, Tian X, Liu H, Yu B. Global Prevalence of Overactive Bladder: A Systematic Review and Meta-analysis. Int Urogynecol J. 2025;36(8):1547-1566. doi:10.1007/s00192-024-06029-2
5. Corcos J, Przydacz M, Campeau L, et al. CUA guideline on adult overactive bladder. Can Urol Assoc J. 2017;11(5):E142-E173. doi:10.5489/cuaj.4586
6. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline part I—initial work-up and medical management. J Urol. 2021;206(4):806-817. doi:10.1097/JU.0000000000002183
7. Andersson KE, Uvelius B. Changes in the rat urinary bladder after the relief of outflow obstruction – tracing targets for treatment of persistent symptoms in patients. Front Urol. 2022;2:1027086. doi:10.3389/fruro.2022.1027086
8. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306-1315. doi:10.1016/j.eururo.2006.09.019
9. Deters LA. Benign prostatic hyperplasia (BPH). Medscape. Updated March 22, 2023. Accessed June 24, 2026. https://emedicine.medscape.com/article/437359-print
10. Dmochowski RR, Gomelsky A. Overactive bladder in males. Ther Adv Urol. 2009;1(4):209-221. doi:10.1177/1756287209350383
11. Burnett AL, Walker DR, Feng Q, et al. Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study. Neurourol Urodyn. 2020;39(5):1378-1386. doi:10.1002/nau.24348
12. Anger JT, Goldman HB, Luo X, et al. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States. Neurourol Urodyn. 2018;37(1):213-222. doi:10.1002/nau.23276
13. Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K, Mujais S. Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. J Urol. 2024;212(2):256-266. doi:10.1097/JU.0000000000003999
14. Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. J Urol. 2020;204(2):316-324. doi:10.1097/JU.0000000000000807

CONTACT INFORMATION FOR KNIGHT:

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia	Arvind Utchanah
President & Chief Executive Officer	Chief Financial Officer
T: 514.484.4483	T: 514.484.4483
Email: IR@knighttx.com	Email: IR@knighttx.com
Website: www.knighttx.com	Website: www.knighttx.com

This press release was published by a CLEAR® Verified individual.

Vancouver, BC, Sept. 15, 2026 (GLOBE NEWSWIRE) — Trident Resources Corp. (TSXV: ROCK) (OTCQB: TRDTF) (Frankfurt: 6BP0) (“Trident” or the “Company”) is pleased to announce that the fixed-wing low level tight drape high resolution radiometric and magnetic survey over the Reindeer Gold Project (the “Reindeer Project”) has been completed. The survey comprised over 6,600-line km and covered the entirety of the early stage 29,300-hectare property located in Saskatchewan’s underexplored La Ronge Gold Belt (“LRGB”).

Reindeer Gold Project Survey Details:

The Reindeer Project is host to multiple documented mineral occurrences and straddles over 40km of the Duck Lake Shear Zone, an important geologic structure that marks the contact between the La Ronge and Kisseynew lithostructural domains. This boundary is intimately associated with several past-producing mines, existing gold deposits and numerous gold occurrences throughout the LRGB.

The combined radiometric and magnetic survey featured 50m line spacing with 250m tie-lines to produce high-resolution data that will help to delineate lithologic boundaries and geologic structures that could host undiscovered gold deposits. The survey area at Reindeer also features three distinct strands of the regional Tabbenor Fault System, host to SSR’s Seabee Gold Project located 80km south of Reindeer.

 Reindeer Project Map:
https://www.tridentresourcescorp.com/_resources/maps/Reindeer-Property-Map.jpg

Contact Lake Drone Magnetic Survey:

In addition to the airborne geophysical survey over Reindeer, Trident also announces that a tightly spaced (25m) drone magnetic survey is underway at the Contact Lake Gold Property. The drone-based survey will cover a large (8 km²) area that includes the Contact Lake mine site and an area that hosts intersecting shear structures with coincident gold-in-soil and gold-in-rock anomalies.

In 2026, Trident has already completed over 2500 soil samples in the area encompassed by the drone survey. The combined surface, magnetic and existing drill data will be used to understand the controlling structures and locate near-term drill targets at Contact Lake.

Contact Lake 2026 Exploration Program Update:

The 2026 summer drill program at Contact Lake has just surpassed 11,000m of an anticipated 20,000m. Drilling is focused on extending the known high-grade mineralization at depth and along strike.

In addition to the ambitious drill program, Trident is conducting a comprehensive soil sampling program (9000 samples) at both Contact Lake and the adjacent Preview project, which hosts the Preview SW and Preview North deposits.

Soil grids at Preview will cover highly prospective areas along the Preview mineralized trend between the two deposits and southwest of Preview SW, where existing magnetic survey data outlines compelling exploration targets. 

Contact Lake Gold Property Map:
http://www.tridentresourcescorp.com/_resources/maps/contact-lake-property-map.jpg

Contact Lake Gold Project Overview:

The Contact Lake Gold Project covers approximately 22,790 hectares and includes the past-producing Contact Lake gold mine, which produced approx. 190,000 ounces of gold at an average head grade of 6.16 g/t Au during active mining operations between 1994 to 1998.

At the time of mine closure, the price of gold hovered around $300/oz (USD) and Cameco Corporation reported that substantial gold resources were left unmined. Situated in the highly prospective La Ronge Gold Belt of Saskatchewan, the Contact Lake Property also hosts the Preview SW, Preview North and the North Lake orogenic gold deposits.

Along with the Greywacke North deposit (located by road 40km northeast of Contact Lake), these four deposits are wholly-owned by Trident Resources and host current Mineral Resource Estimates (Trident news release November 24, 2025) which do not include any gold-related ounces from the past-producing Contact Lake target area.

District-Scale Exploration Strategy:

Trident intends to advance its assets in the under-explored LRGB through focused drilling, prospecting, surface sampling and geophysical surveys to unlock potentially immense value in an emerging gold-rich district.

Trident’s large land package of 98,700 hectares within the LRGB is strategically located to cover numerous mineral occurrences associated with the highly prospective boundary between the La Ronge and Kisseynew lithostructural domains, a compelling exploration target area that helps forms the thesis of Trident’s exploration strategy.

Trident’s Regional Project Location Map:
https://www.tridentresourcescorp.com/projects/contact-lake-gold-project/#&gid=1&pid=1

“We continue to build out the compelling district and regional-scale potential of the La Ronge Gold Belt,” said Jon Wiesblatt, CEO of Trident Resources. “Our expansive land position of nearly 100,000 hectares gives Trident a critical competitive advantage in this emerging gold district, underpinning a resource base of over 2.0 million ounces across four wholly-owned deposits – and notably, this figure excludes any ounces from our past-producing, high-grade Contact Lake gold mine, which we believe holds substantial additional upside.

With a strong balance sheet and a fully funded 2026 exploration program, Trident is well positioned to aggressively advance its district-scale strategy. Looking ahead, shareholders can expect a steady stream of catalysts over the remainder of the year, including assay results from our 20,000 metre summer and fall drill programs, as we work to unlock the full potential of the belt.”

Reindeer Project Acquisition Details:

The Company elected to accelerate its earn-in on the Reindeer Project and has issued 1,000,000 common shares of the Company to Reinco Exploration Limited (“Reinco”) to complete the acquisition of a 100% interest in the Reindeer Project, ahead of the schedule set out in the original option agreement.

Under the option agreement dated September 8, 2025, Trident could earn up to a 100% interest in the Reindeer Project in three stages: a 50% interest through a $35,000 cash payment and the issuance of 1,000,000 common shares at closing; a 75% interest through the issuance of a further 500,000 common shares within the first anniversary of the agreement; and a 100% interest through the issuance of a final 500,000 common shares within the second anniversary.

Having already completed the first stage, the Company has now opted to accelerate and complete the remaining two stages together, issuing the combined 1,000,000 common shares to bring its interest in the Reindeer Project to 100%, well ahead of the original timeline.

All shares issued to Reinco remain subject to a four-month statutory hold period in accordance with applicable securities laws and the policies of the TSX Venture Exchange.

Qualified Person:

The technical information in this news release has been prepared in accordance with the Canadian regulatory requirements set out in National Instrument 43-101 and reviewed and approved by Cornell McDowell, P.Geo., VP Exploration for Trident Resources and the Qualified Person for Trident as defined by NI 43-101.

About Trident Resources Corp.

Trident Resources Corp. is a Canadian gold exploration company focused on advancing district-scale opportunities in Saskatchewan’s La Ronge Gold Belt. The Company has assembled a large and strategic land position encompassing the several gold projects, which host foundational gold resources, together with a growing portfolio of highly prospective regional exploration properties. 

Trident’s current exploration focus is at the 100%-owned Contact Lake Gold Project, host to a past-producing high-grade gold mine where active drill programs are underway to expand known mineralization and unlock the broader district-scale potential of the belt. Backed by a strong treasury as well as an experienced technical and capital markets team, Trident is advancing multiple opportunities with the goal of becoming a leading explorer in one of Canada’s emerging gold districts

To find out more about Trident Resources Corp. (TSX-V: ROCK) visit the Company’s website at www.tridentresourcescorp.com.

TRIDENT RESOURCES CORP.

“Jon Wiesblatt”
                                                                               
Jonathan Wiesblatt
CEO and Director

For further information, please contact:
Jonathan Wiesblatt, Chief Executive Officer
Email: Jon.Wiesblatt@tridentresourcescorp.com

Or:

Lubica Keighery, Corporate Communications
Email: lubica.keighery@tridentresourcescorp.com

Trident Resources Corp.
Telephone: 778-889-5476
Toll Free: 800-567-8181
Facsimile: 604-687-3119

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Forward-Looking Information

This news release contains “forward‐looking information or statements” within the meaning of applicable securities laws, which may include, without limitation, completing ongoing and planned work on its projects including drilling and the expected timing of such work programs, other statements relating to the technical, financial and business prospects of the Company, its projects and other matters. All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of uranium, the ability to achieve its goals, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms. Such forward-looking information reflects the Company’s views with respect to future events and is subject to risks, uncertainties and assumptions, including the risks and uncertainties relating to the interpretation of exploration results, risks related to the inherent uncertainty of exploration and cost estimates and the potential for unexpected costs and expenses, and those filed under the Company’s profile on SEDAR+ at www.sedarplus.ca. Factors that could cause actual results to differ materially from those in forward looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, adverse weather or climate conditions, failure to obtain or maintain all necessary government permits, approvals and authorizations, failure to obtain or maintain community acceptance (including First Nations), decrease in the price of uranium and other metals, increase in costs, litigation, and failure of counterparties to perform their contractual obligations. The Company does not undertake to update forward‐looking statements or forward‐looking information, except as required by law.

Results continue to validate targeting approach

Vancouver, British Columbia, Sept. 15, 2026 (GLOBE NEWSWIRE) — Assays from three more drill holes at North American Niobium and Critical Minerals Corp.’s (CSE: NIOB) (FSE: KS82.F) (OTCQB: NIOMF) (“NIOB” or the “Company”) Bardy property in Québec confirm previously announced visual observations. Holes BBY-2026-001, BBY-2026-002, and BBY-2026-005 have all intersected pegmatite. These assay results are in addition to those from BBY-2026-006, which intersected an 8.0-metre interval of syenitic pegmatite from 139.70 m to 147.70 m, including a 0.20-metre zone that included allanite in the core.

“The goal of our 2026 diamond drilling program at Bardy was to intersect niobium and rare earth bearing systems,” said Murray Nye, NIOB’s Chief Executive Officer, “and the latest results show that we are on the right track. Bardy’s eight holes were all collared at targets where radon data, high resolution magnetics, and surface mapping all intersect, and we’re pleased that the results continue to be validated.”

Highlights from assays

• Hole BBY-2026-001: 2.05 m from 133.75 m to 135.8 m averaging 0.43% total rare earth oxides (TREO); the composite came from a small syeno-granitic pegmatite intrusion and surrounding rocks. The intrusion was slightly magnetic and contained biotite.

• Hole BBY-2026-002: 14.6 m from 132.4 m to 147 m averaging 0.12% TREO; the composite of high rare earth element (REE) grades was found within an intermediate intrusive rock (monzonite/mangerite) cut by small syeno-granitic pegmatitic injections.

• Smaller intervals with REE ≥ 0.1% that didn’t make it as composites were found in holes BBY-2026-001, BBY-2026-002, and BBY-2026-005. Details are presented in Table 1 and shown on the cross sections of figures 1 and 2, along with the composites.

Table 1: Additional intervals TREO% results

Hole ID	From (m)	To (m)	Length (m)	TREO (%)	Rock type
BBY-2026-001	16	17.5	1.5	0.12	Magnetic leuconorite
BBY-2026-001	104.2	104.95	0.75	0.29	Pegmatite with biotite-magnetite clusters and local radioactivity halo, trace allanite locally
BBY-2026-001	104.95	105.7	0.75	0.31
BBY-2026-002	34	34.95	0.95	0.14	Magnetic pegmatite
BBY-2026-002	82	83.1	1.1	0.12	Locally magnetic pegmatite
BBY-2026-005	145.5	146.7	1.2	0.1	Pegmatite dyke with 10% magnetite

Note: Composite intervals were calculated with a cutoff grade of 0.1% TREO, and a maximum of 2 m of internal dilution.

Drilling and geological context
Bardy is part of NIOB’s district-scale critical-minerals land package in Québec’s Grenville Province.

Holes BBY-2026-001 and BBY-2026-002 are located to the East of the Bardy showing, and hole BBY-2026-005 is located to the West (Figure 3). BBY-2026-001 and BBY-2026-005 were meant to test lateral continuity of Bardy’s mineralized dyke. BBY-2026-002 was testing a N110˚ radon anomaly trend.

All holes intersected sequences of intrusive rocks (from felsic to mafic) cutting through the gneiss. Small (< 3 m) pegmatite injections are seen in all three holes.

The presence of allanite within the REE-bearing rocks was noted locally, but magnetite is present in all contexts.

It was also noted that, even if pegmatites are the main REE-hosting rocks, other intrusives (mafic to intermediate) could also bear mineralization. This is interesting knowing the Bardy sector has a complex intrusion history that has yet to be clarified.

Hole BBY-2026-001 was collared at 619303E/ 5271335N (UTM NAD83 Zone 18) and drilled at an azimuth of 10˚ and a dip of -50˚. It reached a depth of 150 m.

Hole BBY-2026-002 was also collared at 619303E/ 5271335N (UTM NAD83 Zone 18) and drilled at an azimuth of 190˚ and a dip of -50˚. It reached a depth of 153 m.

Hole BBY-2026-005 was collared at 619142E/ 5271187N (UTM NAD83 Zone 18) and drilled at an azimuth of 0˚ and a dip of -50˚. It reached a depth of 150 m.

Next Steps

1. Sample the remaining monzonite from 102.6m to 132.4m in hole BBY-2026-002 for REE with additional WRA (whole rock analysis) to best qualify the host rock.
2. Follow-up on upcoming assay results on the Bardy sector for a broader interpretation.

Figure 1: Cross section showing drillholes BBY-2026-001 and -002 with associated TREO assays and composites.

Please click to view image

Figure 2: Cross section showing drillhole BBY-2026-005 with associated TREO assays.

Please click to view image

Figure 3: Map of the Bardy sector with interpreted radon anomaly trends and main dyke extension.

Please click to view image

Quality assurance and quality control
Samples were submitted to SGS Canada Inc. Rare earth elements were determined by sodium-peroxide-fusion ICP-MS (SGS method GE_IMS91A50).

Quality control included certified reference materials, blanks and field duplicates inserted into the sample stream (approximately 13% of submitted samples). The reported samples are NQ-size half-core, split along the core axis and sampled over intervals of approximately 0.5 to 1.0 m, with the remaining half-core retained for reference.

Core recovery through the mineralized intervals averaged approximately 95-97% and is not considered to have materially affected sample representivity.

SGS Canada Inc. is independent of the Company and operates an ISO/IEC 17025-accredited analytical facility at Val d’Or, Québec.

Qualified Person
The scientific and technical information contained in this news release has been prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”). Clyde McMillan, P.Geo., a consultant to the Company and a Qualified Person as defined under NI 43-101, has reviewed and approved the technical information contained herein.

ABOUT NORTH AMERICAN NIOBIUM AND CRITICAL MINERALS CORP.
North American Niobium and Critical Minerals Corp. is a North American mineral exploration company focused on the acquisition and development of precious, base, and critical mineral assets. Its portfolio includes the Silver Lake property in British Columbia’s Omineca Mining Division and a district-scale land package covering 29,936 hectares in Quebec’s Grenville Province. The Quebec properties host rare earth element, niobium, and nickel-copper occurrences, expanding the Company’s footprint into critical minerals that are strategically important for energy and defense applications.

ON BEHALF OF THE BOARD OF DIRECTORS:
Murray Nye
Chief Executive Officer
info@northamericanniobium.com
+1 (647) 984-4204

Forward-Looking Statements
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, “will”, “plans”, “continues” and similar expressions, or statements that events, conditions or results “will”, “may”, “could” or “should” occur or be achieved.

Forward-looking statements in this news release include, but are not limited to, statements regarding the Company’s plans to complete additional sampling and whole-rock analysis of drill hole BBY-2026-002, the receipt and interpretation of additional assay results from the Bardy sector, further geological interpretation of the Bardy mineralized system, and the potential for future exploration programs to identify additional rare earth element or other critical-mineral mineralization.

Forward-looking statements are based on assumptions management believes to be reasonable and are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially, including the possibility that additional assay results may not be consistent with results reported to date, that geological interpretations may change as additional information becomes available, that mineralized intervals may not demonstrate continuity, and risks relating to mineral exploration and development, the availability of financing, laboratory and analytical delays, changes in commodity prices and the other risk factors discussed in the Company’s continuous-disclosure documents filed under its profile on SEDAR+ at www.sedarplus.ca.

The forward-looking statements in this news release are made as of the date hereof. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved the contents of this press release.